TY - JOUR
T1 - How to Report PSMA PET
AU - Swiha, Mina
AU - Ayati, Narjess
AU - Oprea-Lager, Daniela E.
AU - Ceci, Francesco
AU - Emmett, Louise
N1 - Funding Information: None. Publisher Copyright: © 2023 Elsevier Inc.
PY - 2024/1
Y1 - 2024/1
N2 - Prostate cancer (PCa) is the most common cancer diagnosed in men in most developed countries and a leading cause of cancer-related morbidity and mortality. Prostate-specific membrane antigen positron emission tomography (PSMA-PET) has become a valuable tool in the staging and assessment of disease recurrence in PCa, and more recently for assessment for treatment eligibility to PSMA radioligand therapy (RLT). Harmonization of PSMA-PET interpretation and synoptic reports are needed to communicate concisely and reproducibly PSMA-PET/CT to referring physicians and to support clinician therapeutic management decisions in various stages of the disease. Uniform image interpretation is also important to provide comparable data between clinical trials and to translate such data from research to daily practice. This review provides an overview of the value of PSMA-PET across the different clinical stages of PCa, discusses published reporting criteria for PSMA-PET, identifies pitfalls in reporting PSMA, and provides recommendations for synoptic reports.
AB - Prostate cancer (PCa) is the most common cancer diagnosed in men in most developed countries and a leading cause of cancer-related morbidity and mortality. Prostate-specific membrane antigen positron emission tomography (PSMA-PET) has become a valuable tool in the staging and assessment of disease recurrence in PCa, and more recently for assessment for treatment eligibility to PSMA radioligand therapy (RLT). Harmonization of PSMA-PET interpretation and synoptic reports are needed to communicate concisely and reproducibly PSMA-PET/CT to referring physicians and to support clinician therapeutic management decisions in various stages of the disease. Uniform image interpretation is also important to provide comparable data between clinical trials and to translate such data from research to daily practice. This review provides an overview of the value of PSMA-PET across the different clinical stages of PCa, discusses published reporting criteria for PSMA-PET, identifies pitfalls in reporting PSMA, and provides recommendations for synoptic reports.
UR - http://www.scopus.com/inward/record.url?scp=85167813863&partnerID=8YFLogxK
U2 - https://doi.org/10.1053/j.semnuclmed.2023.07.007
DO - https://doi.org/10.1053/j.semnuclmed.2023.07.007
M3 - Review article
C2 - 37558507
SN - 0001-2998
VL - 54
SP - 14
EP - 29
JO - Seminars in Nuclear Medicine
JF - Seminars in Nuclear Medicine
IS - 1
ER -